DeepMed Research

Infinity Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2001-01-01

Employees: 51

Market Cap: -

Website: http://www.infi.com

Clinical Trials

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Phase 2

Withdrawn

Conditions: Dedifferentiated Liposarcoma

Interventions: Drug: IPI-504

First Posted Date: 2009-09-02

Last Posted Date: 2015-04-14

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Registration Number: NCT00969917

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
HER2 Positive Breast Cancer
Metastatic Breast Cancer
Cancer of the Breast

Interventions: Drug: IPI-504
Drug: Trastuzumab

First Posted Date: 2009-01-06

Last Posted Date: 2012-12-11

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 29

Registration Number: NCT00817362

Locations: 🇺🇸
Boca Raton Comphrensive Cancer Care, Boca Raton, Florida, United States
🇺🇸
Medical College of Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States

and more 8 locations

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: IPI-926

First Posted Date: 2008-09-29

Last Posted Date: 2012-06-21

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 94

Registration Number: NCT00761696

Locations: 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States
🇺🇸
TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
Stanford University, Redwood City, California, United States

and more 2 locations

A Phase 1 Dose Escalation Study of IPI-493

Phase 1

Terminated

Conditions: Advanced Malignancies

First Posted Date: 2008-07-29

Last Posted Date: 2015-04-15

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 53

Registration Number: NCT00724425

Locations: 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸
Premiere Oncology, Arizona, Scottsdale, Arizona, United States
🇺🇸
Univeristy of Colorado Health Science Center, Aurora, Colorado, United States

and more 2 locations

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Phase 3

Terminated

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: retaspimycin hydrochloride (IPI-504)
Drug: placebo
Other: Best supportive care

First Posted Date: 2008-06-03

Last Posted Date: 2012-12-11

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 47

Registration Number: NCT00688766

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma

Interventions: Drug: IPI-504

First Posted Date: 2008-03-03

Last Posted Date: 2012-12-10

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 1

Registration Number: NCT00627419

Locations: 🇺🇸
Washington School of Medicine, St. Louis, Missouri, United States
🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States

and more 14 locations

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

First Posted Date: 2008-02-05

Last Posted Date: 2012-03-06

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT00606814

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Gabrail Cancer Center, Dover, Ohio, United States

and more 4 locations

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Prostatic Neoplasms
Cancer of the Prostate

Interventions: Drug: IPI-504

First Posted Date: 2007-11-29

Last Posted Date: 2012-12-11

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 19

Registration Number: NCT00564928

Locations: 🇺🇸
University of Colorado at Denver, Denver, Colorado, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 7 locations

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2007-02-02

Last Posted Date: 2012-12-10

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 88

Registration Number: NCT00431015

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 8 locations

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Phase 1

Completed

Conditions: Gastrointestinal Stromal Tumors
Soft Tissue Sarcomas

Interventions: Drug: IPI-504

First Posted Date: 2006-01-13

Last Posted Date: 2011-01-06

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 63

Registration Number: NCT00276302

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Premiere Oncology, Santa Monica, California, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy